ARHI在卵巢癌中的研究进展  

Research Progress of ARHI in Ovarian Cancer

作　　者：陈永昌 王静 吴娜怡园 刘路 CHEN Yongchang;WANG Jing;WU Nayiyuan;LIU Lu(University of South China,Hengyang,Hunan,421001,China;Clinical Medical Research Center of Gynecologic Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,Hunan,410013,China)

机构地区：[1]南华大学,湖南衡阳421001 [2]湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院妇科肿瘤临床医学研究中心,湖南长沙410013

出　　处：《肿瘤药学》2019年第6期833-838,共6页Anti-Tumor Pharmacy

基　　金：十三五科技部国家重点研发计划“慢病非传染性疾病防控研究重点专项”;湖南省科技厅项目(2016SK4005);湖南省妇科肿瘤临床医学研究中心项目(2016YFC1303703)

摘　　要：卵巢癌是全球范围内影响女性生命健康的疾病。由于卵巢癌早期缺乏特异性表现,发现时大多已经转移,故死亡率较高,并且相当比例的卵巢癌患者化疗后会出现复发和耐药,总体治疗效果欠佳。目前,从分子生物学角度治疗癌症已成为研究热点。已有研究表明,ARHI作为一种抑癌基因,与卵巢癌有着密切的关系。本文主要对ARHI基因在卵巢癌中的研究进展进行综述。Ovarian cancer is a disease that affects women’s life and health worldwide.Due to the lack of characteristic features of ovarian cancer in the early stage,most of the ovarian cancer patients have metastasis when diagnosed.Yet a great proportion of ovarian cancer patients have recurrence and drug resistance after chemotherapy.The overall treatment effect is consequently poor and the mortality is high for ovarian cancer patients.At present,it is a general trend to treat cancer from the perspective of molecular biology.Studies have shown that ARHI,as a tumor suppressor gene,has a close relationship with ovarian cancer.This review summarized the research progress of ARHI gene in ovarian cancer.

关 键 词：ARHI 卵巢癌 自噬 化疗耐药 

分 类 号：R737.31[医药卫生—肿瘤]